Algert Global LLC Grows Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Algert Global LLC boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 8.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 74,984 shares of the biotechnology company's stock after purchasing an additional 5,778 shares during the period. Algert Global LLC owned about 0.08% of Sarepta Therapeutics worth $9,117,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Tidal Investments LLC raised its position in shares of Sarepta Therapeutics by 91.2% during the third quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company's stock worth $704,000 after acquiring an additional 2,688 shares during the last quarter. GAMMA Investing LLC grew its position in Sarepta Therapeutics by 27.7% in the 4th quarter. GAMMA Investing LLC now owns 854 shares of the biotechnology company's stock valued at $104,000 after purchasing an additional 185 shares during the period. Everence Capital Management Inc. bought a new position in Sarepta Therapeutics in the 4th quarter valued at about $344,000. Nordea Investment Management AB raised its position in Sarepta Therapeutics by 19.1% in the 4th quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company's stock valued at $8,228,000 after buying an additional 10,815 shares during the last quarter. Finally, ORG Partners LLC boosted its stake in shares of Sarepta Therapeutics by 17.6% in the 4th quarter. ORG Partners LLC now owns 2,000 shares of the biotechnology company's stock worth $243,000 after buying an additional 300 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT traded down $10.03 during mid-day trading on Wednesday, hitting $36.72. 20,719,614 shares of the company's stock traded hands, compared to its average volume of 1,565,504. The company has a market capitalization of $3.61 billion, a P/E ratio of 29.38 and a beta of 0.85. Sarepta Therapeutics, Inc. has a 1 year low of $36.49 and a 1 year high of $173.25. The company's 50-day moving average is $69.47 and its two-hundred day moving average is $102.12. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The business had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The business's revenue was up 80.2% compared to the same quarter last year. During the same period last year, the company earned $0.73 EPS. On average, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft dropped their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research report on Wednesday, March 19th. Wells Fargo & Company started coverage on shares of Sarepta Therapeutics in a research note on Friday, April 11th. They set an "overweight" rating and a $115.00 price objective for the company. Guggenheim dropped their target price on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a research report on Wednesday. Needham & Company LLC lowered their price objective on Sarepta Therapeutics from $183.00 to $125.00 and set a "buy" rating for the company in a research report on Wednesday. Finally, Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $110.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $137.09.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.